Summit Therapeutics, with the ticker SMMT, saw a significant rise of 13% in its stock price, reaching $29.79. This jump came after the company released promising results from its HARMONi trial. Investors appear optimistic about the potential implications of these findings, which contribute to the upward momentum in the stock's value.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Summit Therapeutics Inc (SMMT, Financial) is $33.78 with a high estimate of $44.00 and a low estimate of $5.00. The average target implies an upside of 28.87% from the current price of $26.21. More detailed estimate data can be found on the Summit Therapeutics Inc (SMMT) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Summit Therapeutics Inc's (SMMT, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
